212 related articles for article (PubMed ID: 19052742)
1. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma.
Gordon IO; Wade T; Chin K; Dickstein J; Gajewski TF
Cancer Immunol Immunother; 2009 Aug; 58(8):1351-3. PubMed ID: 19052742
[No Abstract] [Full Text] [Related]
2. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.
Di Giacomo AM; Danielli R; Guidoboni M; Calabrò L; Carlucci D; Miracco C; Volterrani L; Mazzei MA; Biagioli M; Altomonte M; Maio M
Cancer Immunol Immunother; 2009 Aug; 58(8):1297-306. PubMed ID: 19139884
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia.
Nair R; Gheith S; Nair SG
N Engl J Med; 2016 Mar; 374(11):1096-7. PubMed ID: 26981948
[No Abstract] [Full Text] [Related]
4. CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.
Yuan J; Gnjatic S; Li H; Powel S; Gallardo HF; Ritter E; Ku GY; Jungbluth AA; Segal NH; Rasalan TS; Manukian G; Xu Y; Roman RA; Terzulli SL; Heywood M; Pogoriler E; Ritter G; Old LJ; Allison JP; Wolchok JD
Proc Natl Acad Sci U S A; 2008 Dec; 105(51):20410-5. PubMed ID: 19074257
[TBL] [Abstract][Full Text] [Related]
5. Ipilimumab: a promising immunotherapy for melanoma.
Thumar JR; Kluger HM
Oncology (Williston Park); 2010 Dec; 24(14):1280-8. PubMed ID: 21294471
[TBL] [Abstract][Full Text] [Related]
6. A case of immune thrombocytopaenia induced by pembrolizumab in a metastatic melanoma patient with a history of immune-mediated pure red cell aplasia.
Berger M; Amini-Adlé M; Crumbach L; Paubelle E; Dalle S
Eur J Cancer; 2019 May; 112():94-97. PubMed ID: 30954716
[No Abstract] [Full Text] [Related]
7. CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.
Yuan J; Ginsberg B; Page D; Li Y; Rasalan T; Gallardo HF; Xu Y; Adams S; Bhardwaj N; Busam K; Old LJ; Allison JP; Jungbluth A; Wolchok JD
Cancer Immunol Immunother; 2011 Aug; 60(8):1137-46. PubMed ID: 21465316
[TBL] [Abstract][Full Text] [Related]
8. Cancer Immunotherapy with Anti-CTLA-4 Monoclonal Antibodies Induces an Inflammatory Bowel Disease.
Marthey L; Mateus C; Mussini C; Nachury M; Nancey S; Grange F; Zallot C; Peyrin-Biroulet L; Rahier JF; Bourdier de Beauregard M; Mortier L; Coutzac C; Soularue E; Lanoy E; Kapel N; Planchard D; Chaput N; Robert C; Carbonnel F
J Crohns Colitis; 2016 Apr; 10(4):395-401. PubMed ID: 26783344
[TBL] [Abstract][Full Text] [Related]
9. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma.
du Rusquec P; Saint-Jean M; Brocard A; Peuvrel L; Khammari A; Quéreux G; Dréno B
J Immunother; 2014; 37(6):348-50. PubMed ID: 24911795
[TBL] [Abstract][Full Text] [Related]
10. Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.
Wilgenhof S; Neyns B
Ann Oncol; 2011 Apr; 22(4):991-993. PubMed ID: 21357649
[No Abstract] [Full Text] [Related]
11. Neutropenia in a patient treated with ipilimumab (anti-CTLA-4 antibody).
Akhtari M; Waller EK; Jaye DL; Lawson DH; Ibrahim R; Papadopoulos NE; Arellano ML
J Immunother; 2009 Apr; 32(3):322-4. PubMed ID: 19242368
[TBL] [Abstract][Full Text] [Related]
12. Autoimmune inflammatory myopathy after treatment with ipilimumab.
Hunter G; Voll C; Robinson CA
Can J Neurol Sci; 2009 Jul; 36(4):518-20. PubMed ID: 19650371
[No Abstract] [Full Text] [Related]
13. Improved survival with ipilimumab in patients with metastatic melanoma.
Hodi FS; O'Day SJ; McDermott DF; Weber RW; Sosman JA; Haanen JB; Gonzalez R; Robert C; Schadendorf D; Hassel JC; Akerley W; van den Eertwegh AJ; Lutzky J; Lorigan P; Vaubel JM; Linette GP; Hogg D; Ottensmeier CH; Lebbé C; Peschel C; Quirt I; Clark JI; Wolchok JD; Weber JS; Tian J; Yellin MJ; Nichol GM; Hoos A; Urba WJ
N Engl J Med; 2010 Aug; 363(8):711-23. PubMed ID: 20525992
[TBL] [Abstract][Full Text] [Related]
14. Anti-CTLA4 monoclonal antibody Ipilimumab in the treatment of metastatic melanoma: recent findings.
Lens M; Ferrucci PF; Testori A
Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):105-13. PubMed ID: 18537753
[TBL] [Abstract][Full Text] [Related]
15. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
Phan GQ; Weber JS; Sondak VK
Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
[TBL] [Abstract][Full Text] [Related]
16. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
Weber J
Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
[TBL] [Abstract][Full Text] [Related]
17. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma.
Phan GQ; Yang JC; Sherry RM; Hwu P; Topalian SL; Schwartzentruber DJ; Restifo NP; Haworth LR; Seipp CA; Freezer LJ; Morton KE; Mavroukakis SA; Duray PH; Steinberg SM; Allison JP; Davis TA; Rosenberg SA
Proc Natl Acad Sci U S A; 2003 Jul; 100(14):8372-7. PubMed ID: 12826605
[TBL] [Abstract][Full Text] [Related]
18. Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management.
Savoia P; Astrua C; Fava P
Hum Vaccin Immunother; 2016 May; 12(5):1092-101. PubMed ID: 26889818
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anti-PD-1 and anti-PD-1 combined with anti-CTLA-4 immunotherapy to advanced melanoma: A systematic review and meta-analysis of randomized controlled trials.
Hao C; Tian J; Liu H; Li F; Niu H; Zhu B
Medicine (Baltimore); 2017 Jun; 96(26):e7325. PubMed ID: 28658143
[TBL] [Abstract][Full Text] [Related]
20. Treating cancer by targeting the immune system.
Hwu P
N Engl J Med; 2010 Aug; 363(8):779-81. PubMed ID: 20818880
[No Abstract] [Full Text] [Related]
[Next] [New Search]
